Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Acrivon Therapeutics (NASDAQ:ACRV) in a report published on Wednesday,Benzinga reports.

A number of other equities analysts have also weighed in on the company. KeyCorp started coverage on Acrivon Therapeutics in a research note on Friday, January 31st. They set an “overweight” rating on the stock. HC Wainwright lowered their price target on shares of Acrivon Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.17.

Acrivon Therapeutics Price Performance

ACRV opened at $2.61 on Wednesday. The firm has a market capitalization of $81.26 million, a price-to-earnings ratio of -0.97 and a beta of 0.85. The company’s 50 day simple moving average is $5.48 and its two-hundred day simple moving average is $6.60. Acrivon Therapeutics has a 1-year low of $2.51 and a 1-year high of $11.90.

Institutional Trading of Acrivon Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in Acrivon Therapeutics in the fourth quarter valued at about $40,000. Wealthedge Investment Advisors LLC acquired a new position in shares of Acrivon Therapeutics in the 4th quarter worth approximately $65,000. Corton Capital Inc. purchased a new position in shares of Acrivon Therapeutics during the 4th quarter worth approximately $73,000. American Century Companies Inc. increased its holdings in Acrivon Therapeutics by 14.2% in the 4th quarter. American Century Companies Inc. now owns 17,588 shares of the company’s stock valued at $106,000 after purchasing an additional 2,186 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in Acrivon Therapeutics by 20.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 37,063 shares of the company’s stock valued at $223,000 after purchasing an additional 6,239 shares during the period. 71.62% of the stock is owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.